Nonalcoholic fatty liver disease (NAFLD) is a progressive condition characterized by the accumulation of fat in the liver cells, not caused by alcohol consumption. It is one of the most common liver diseases worldwide and is associated with conditions like obesity and type 2 diabetes.
NAFLD ranges from simple fatty liver (steatosis) to nonalcoholic steatohepatitis (NASH), which can progress to cirrhosis or liver cancer in severe cases. One of the challenges with NAFLD is that it often shows no symptoms until it has significantly progressed. However, some people may experience fatigue, discomfort in the upper right abdomen, and unexplained weight loss.
The primary treatment for NAFLD involves managing risk factors and associated conditions. This includes losing weight if overweight or obese, controlling blood sugar if diabetic, reducing cholesterol levels, and increasing physical activity. There are currently no approved medications for NAFLD, but some drugs are being studied.
Preventing NAFLD primarily involves leading a healthy lifestyle. Maintaining a balanced diet, regular exercise, avoiding alcohol and unnecessary medications, and regular check-ups to monitor liver health are all crucial steps.
While NAFLD can be a silent and potentially dangerous condition, early detection and appropriate lifestyle modifications can halt its progression and even reverse some of the damage. Regular monitoring and health check-ups are crucial for individuals with risk factors such as obesity, type 2 diabetes, and high cholesterol levels.
- Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., ... & Bugianesi, E. (2018). Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nature Reviews Gastroenterology & Hepatology, 15(1), 11-20.
- Rinella, M. E. (2015). Nonalcoholic fatty liver disease: a systematic review. JAMA, 313(22), 2263-2273.
- Loomba, R., & Sanyal, A. J. (2013). The global NAFLD epidemic. Nature Reviews Gastroenterology & Hepatology, 10(11), 686-690.
- Vilar-Gomez, E., & Chalasani, N. (2018). Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. Journal of Hepatology, 68(2), 305-315.
- Bower, G., Toma, T., Harling, L., Jiao, L. R., Efthimiou, E., Darzi, A., ... & Athanasiou, T. (2015). Bariatric surgery and non-alcoholic fatty liver disease: a systematic review of liver biochemistry and histology. Obesity surgery, 25(12), 2280-2289.